Clinical Trial Update: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating obinutuzumab, polatuzumab vedotin, and lenalidomide in relapsed or refractory follicular lymphoma and rituximab with polatuzumab vedo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)
• polatuzumab vedotin + rituximab + lenalidomide

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-12-26